Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

washington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHA
obligations may continue. See	

NGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Durso-Bumpus Debra (Last) (First) (Middle)						Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [BPMC] Jate of Earliest Transaction (Month/Day/Year)									ationship of Reporting k all applicable) Director Officer (give title below)		-	10% Ov Other (s below)	rner		
	JEPRINT N EY STREE	MEDICINES CO	RPOR	ATION		09/23/2021									Chief People Officer						
(Street)	IDGE M		02139		_ 4. lf	4. If Amendment, Date of Orig					Original Filed (Month/Day/Year)				lividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S		(Zip)	on Deriv	rative	Soc	uritia	oc A	- auiro	4 D	ienocod (of or Be	nofici	ally C)wnor	1					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)				tion	on 2A. Deemed Execution Date,			3. 4. Securities			es Acquired (A) or Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	- 1-		action(s) 3 and 4)			(Instr. 4)			
Common Stock 09/23/2				2021)21		M ⁽¹⁾		848	A	\$36.0)5	31	,722		D					
Common	Stock			09/23/2	2021				S ⁽¹⁾		848	D	\$110.0)1 ⁽²⁾	30	30,874 D					
		Т	able II								posed of converti				vned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	ion Date,	4. Transa Code (8)		n of		6. Date I Expirati (Month/I	on Da		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		Deri Sec (Ins	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amoun or Numbe of Shares	1							
Stock Option (Right to Buy)	\$36.05	09/23/2021			M ⁽¹⁾			848	(3)		02/16/2027	Common Stock	848		\$0	27,452	2	D			

Explanation of Responses:

- 1. Effected pursuant to a trading plan adopted on February 19, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.00 to \$110.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth
- 3. This option was granted on February 16, 2017 and fully vested as of the date hereof.

/s/ Ariel Hurley, Attorney-in-

09/27/2021

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.